Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo

References

• Torgerson JS, Hauptman J, Boldrin MN . XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155–61.
   PubMed Web of Science ®Google Scholar
• Davidson MH, Hauptman J, DiGirolamo M . Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999;281:235–42.
   PubMed Web of Science ®Google Scholar
• Sjostrom L, Rissanen A, Andersen T . Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet. 1998;352(9123):167–72.
   PubMed Web of Science ®Google Scholar
• Chanoine JP, Hampl S, Jensen C . Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA. 2005;293(23):2873–83.
   PubMed Web of Science ®Google Scholar
• Viner RM, Hsia Y, Neubert A . Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based study. Br J Clin Pharmacol. 2009;68:844–51.
   Google Scholar
• Rissanen A, Lean M, Rossner S . Predictive value of early weight loss in obesity management with orlistat: an evidence-based assessment of prescribing guidelines. Int J Obes Relat Metab Disord. 2003;27:103–9.
   PubMedGoogle Scholar
• Berkey CS, Colditz GA. Adiposity in adolescents: change in actual BMI works better than change in BMI z score for longitudinal studies. Ann Epidemiol. 2007;17:44–50.
   PubMed Web of Science ®Google Scholar
• Cole TJ, Faith MS, Pietrobelli A . What is the best measure of adiposity change in growing children: BMI, BMI %, BMI z-score or BMI centile? Eur J Clin Nutr. 2005;59: 419–25.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Xenical: Summary of product characteristics. www.ema.europa.eu/humandocs/PDFs/EPAR/Xenical/H-154-PI-en.pdf (Accessed on May 26, 2010)
   Google Scholar
• Lobstein T, Baur L, Uauy R. Obesity in children and young people: a crisis in public health. Obes Rev. 2004;5 Suppl 1:4–104.
   PubMedGoogle Scholar
• Whitlock EP, Williams SB, Gold R . Screening and interventions for childhood overweight: a summary of evidence for the US Preventive Services Task Force. Pediatrics. 2005;116:e125–44.
   PubMed Web of Science ®Google Scholar
• Czernichow S, Lee CM, Barzi F . Efficacy of weight loss drugs on obesity and cardiovascular risk factors in obese adolescents: a meta-analysis of randomized controlled trials. Obes Rev. 2010;11:150–8.
   PubMed Web of Science ®Google Scholar
• Viner RM, Hsia Y, Tomsic T . Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis. Obes Rev. 2010;11:593–602.
   PubMed Web of Science ®Google Scholar
• Reinehr T, Temmesfeld M, Kersting M . Four-year follow-up of children and adolescents participating in an obesity intervention program. Int J Obes (Lond). 2007;31: 1074–7.
   Google Scholar
• Astrup A, Rossner S. Lessons from obesity management programmes: greater initial weight loss improves long-term maintenance. Obes Rev. 2000;1:17–9.
   PubMedGoogle Scholar
• Stotland SC, Larocque M. Early treatment response as a predictor of ongoing weight loss in obesity treatment. Br J Health Psychol. 2005;10 (Pt 4):601–14.
   Google Scholar
• Rogovik A, Chanoine JP, Goldman R. Pharmacotherapy and weight loss supplements for treatment of pediatric obesity. Pediatr Drugs. 2010;70:335–46.
   Google Scholar
• Lau DC, Douketis JD, Morrison KM . 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. CMAJ. 2007;176:S1–13.
   PubMed Web of Science ®Google Scholar
• Sellers EAC. Pharmacotherapy and bariatric surgery for the treatment of obesity in children and adolescents. CMAJ. 2007;176(8):S89–91.
   Google Scholar
• Toplak H, Ziegler O, Keller U . X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance. Diabetes Obes Metab. 2005;7:699–708.
   PubMed Web of Science ®Google Scholar
• Demarchi B, Vos R, Deprez P . Influence of a lipase inhibitor on gastric sensitivity and accommodation to an orally ingested meal. Aliment Pharmacol Ther. 2004;19:1261–8.
   Google Scholar
• Svendsen M, Helgeland M, Tonstad S. The long-term influence of orlistat on dietary intake in obese subjects with components of metabolic syndrome. J Hum Nutr Diet. 2009;22:55–63.
   Google Scholar
• Svendsen M, Rissanen A, Richelsen B . Effect of orlistat on eating behavior among participants in a 3-year weight maintenance trial. Obesity (Silver Spring). 2008;16: 327–33.
   Web of Science ®Google Scholar
• Franson K, Rossner S. Fat intake and food choices during weight reduction with diet, behavioural modification and a lipase inhibitor. J Intern Med. 2000;247(5):607–14.
   Google Scholar
• Damci T, Yalin S, Balci H . Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients. Diabetes Care. 2004;27:1077–80.
   PubMed Web of Science ®Google Scholar
• Sari R, Balci MK, Coban E . Comparison of the effect of orlistat vs orlistat plus metformin on weight loss and insulin resistance in obese women. Int J Obes Relat Metab Disord. 2004;28:1059–63.
   PubMed Web of Science ®Google Scholar
• Erondu N, Addy C, Lu K . NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine. Obesity (Silver Spring). 2007;15:2027–42.
   PubMedGoogle Scholar
• Sari R, Balci MK, Cakir M . Comparison of efficacy of sibutramine or orlistat versus their combination in obese women. Endocr Res. 2004;30:159–67.
   PubMed Web of Science ®Google Scholar
• Kaya A, Aydin N, Topsever P . Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients. Biomed Pharmacother. 2004;58: 582–7.
   PubMed Web of Science ®Google Scholar
• Heal DJ, Aspley S, Prow MR . Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Int J Obes Relat Metab Disord. 1998;22 Suppl 1:S18–28; discussion: S29.
   Google Scholar
• Borgstrom B. Mode of action of tetrahydrolipstatin: a derivative of the naturally occurring lipase inhibitor lipstatin. Biochim Biophys Acta. 1988;962:308–16.
   PubMed Web of Science ®Google Scholar